Clinical Trials Logo

Clinical Trial Summary

This study will examine the role of certain areas of the brain in blepharospasm, a type of dystonia (abnormality of movement and muscle tone) that causes unwanted or uncontrollable blinking or closing of the eyelids. The study will compare brain activity in healthy volunteers and in people with blepharospasm to find differences in the brain that may lead to better treatments for dystonia.

Healthy volunteers and people with blepharospasm who are 18 years of age and older may be eligible for this study. All candidates are screened with a medical history. People with blepharospasm also have a physical examination and blepharospasm rating.

Participants undergo transcranial magnetic stimulation (TMS) and electromyography (EMG) in two 4-hour sessions, separated by 1 to 7 days.

TMS

A wire coil is held on the subject's scalp. A brief electrical current is passed through the coil, creating a magnetic pulse that stimulates the brain. The subject hears a click and may feel a pulling sensation on the skin under the coil. There may be a twitch in muscles of the face, arm or leg. During the stimulation, subjects may be asked to tense certain muscles slightly or perform other simple actions. Repetitive TMS involves repeated magnetic pulses delivered in short bursts of impulses. Subjects receive 60 pulses per minute over 15 minutes.

EMG

Surface EMG is done during TMS to measure the electrical activity of muscles. For this test, electrodes (small metal disks) are filled with a conductive gel and taped to the skin of the face....


Clinical Trial Description

Objectives

This proposal will evaluate the role of an increase in excitability of the orbicularis oculi (OO) muscle representation in the medial frontal areas (supplementary motor areas, SMA) and anterior rostral cingulate: M3) in excessive blinking in patients with benign essential blepharospasm (BEB). We hypothesize that:

1. at rest, the decrease of the MEP after 15 minutes of 1Hz rTMS, targeting the SMA-M3, is more prominent in patients with BEP than in healthy control subjects,

2. at rest, the decrease of the MEP after 15 minutes of 1Hz rTMS targeting M1, is almost the same in patients with BEP and in healthy control subjects,

3. at rest, sICI of OO muscle will be decreased and ICF increased after stimulation of the SMA-M3 facial cortical area, in patients with BEP compared to healthy control subjects,

4. at rest sICI and ICF of the OO muscle will be the same after stimulation of the M1 facial area in patients with BEP and healthy control subjects,

5. in healthy control subjects facilitation of the MEPs evoked from M1 is more prominent during voluntary blinking,

6. in healthy control subjects facilitation of the MEP evoked from SMA-M3 is more prominent during involuntary blinking,

7. in patients with BEB there is facilitation of MEPs evoked from M1 and SMA-M3 during voluntary and involuntary blinking.

8. it is possible to evoke consistent and reproducible motor evoked responses (MEP) in the orbicularis oculi (OO) muscles by stimulating the two main cortical representations of upper facial region: in the medial frontal wall (SMA and cingulate cortex - its rostral part, M3) and in the primary motor cortex (M1) with transcranial magnetic stimulation (TMS).

Study population

36 patients with BEB but without severe forceful closure of eyelids, 36 normal volunteers.

Study design

Subjects will have 3 visits:

Visit 1: screening and blepharospasm score

Visit 2: stimulation of the OO muscle representation in SMA-M3 using low frequency rTMS (1Hz) with the Hesed coil (designed to stimulate deep brain).

Visit 3: stimulation of the OO muscle representation in M1 using low frequency rTMS (1Hz) using a standard eight-shaped coil.

Visits 2 and 3: single pulse TMS will be used to evoke MEPs from OO muscles. Paired pulse TMS will be used to assess sICI from OO muscles. The order of visits 2 and 3 will be randomly assigned.

Outcome measures

The main outcome measures will be the sizes of OO muscle MEPs and the amount of sICI assessed before and after 15 minutes of low frequency rTMS. The secondary outcome measures will be the sizes of OO muscle MEPs assessed before and during voluntary and involuntary blinks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00500799
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase N/A
Start date July 9, 2007
Completion date April 14, 2009

See also
  Status Clinical Trial Phase
Completed NCT01686061 - Blepharospasm Patient Survey for Patients With Blepharospasm
Completed NCT00535938 - MDs on Botox Utility (MOBILITY) N/A
Recruiting NCT05027997 - Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Phase 2
Terminated NCT03263000 - Photic Blink Reflex in People With Blepharospasm and Increased Blinking
Completed NCT03938363 - Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia N/A
Completed NCT02947815 - Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Phase 2/Phase 3
Completed NCT00406367 - IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm Phase 3
Completed NCT00682760 - Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm Phase 3
Completed NCT00210431 - Post Marketing Surveillance Study of Dysport
Completed NCT05103202 - Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
Completed NCT04423341 - Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Phase 2/Phase 3
Completed NCT03269123 - A Mechanical Device for Blepharospasm N/A
Completed NCT00411255 - Brain Stimulation to Treat Blepharospasm or Meige Syndrome Phase 2
Completed NCT00761592 - Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Phase 4
Completed NCT00001784 - Mexiletine for the Treatment of Focal Dystonia Phase 2
Recruiting NCT04939909 - Botulinum Toxin Relieves Anxiety, Depression and Sleep Disorderes in Patients With Blepharospasm Early Phase 1
Completed NCT03508882 - Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Phase 4
Completed NCT01814774 - A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm N/A
Completed NCT00234507 - Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm Phase 2
Recruiting NCT05618470 - Wumeiwan Jiawei Fang Use in Patients With Blepharospasm Phase 2/Phase 3